Addus HomeCare (NASDAQ:ADUS) Stock Gets Price Target Increase from UBS Group

Addus HomeCare (NASDAQ:ADUS) had its target price increased by research analysts at UBS Group from $145.00 to $160.00 in a research note issued to investors on Thursday, Benzinga reports. The firm presently has a “buy” rating on the stock. UBS Group‘s target price points to a potential upside of 28.71% from the stock’s previous close.

A number of other equities research analysts have also recently weighed in on ADUS. Raymond James Financial set a $137.00 price target on Addus HomeCare in a report on Monday, September 28th. Citigroup lowered Addus HomeCare from a “market outperform” rating to a “neutral” rating in a report on Monday, September 14th. Barclays raised their target price on Addus HomeCare from $96.00 to $101.00 and gave the company an “underweight” rating in a research report on Wednesday. Royal Bank Of Canada lifted their target price on Addus HomeCare from $130.00 to $134.00 and gave the company an “outperform” rating in a research note on Wednesday, August 5th. Finally, Weiss Ratings upgraded Addus HomeCare from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday, September 24th. Seven investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $134.70.

Addus HomeCare Stock Performance

NASDAQ ADUS traded down $2.50 during trading hours on Thursday, hitting $124.31. The company had a trading volume of 276,627 shares, compared to its average volume of 212,662. The company has a quick ratio of 1.69, a current ratio of 1.69 and a debt-to-equity ratio of 0.05. The firm has a market cap of $2.32 billion, a P/E ratio of 20.72, a price-to-earnings-growth ratio of 1.79 and a beta of 0.75. Addus HomeCare has a fifty-two week low of $87.95 and a fifty-two week high of $131.59. The business has a fifty day simple moving average of $117.60 and a 200-day simple moving average of $106.88.

Addus HomeCare (NASDAQ:ADUS) last announced its quarterly earnings results on Tuesday, November 3rd. The company reported $1.83 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.79 by $0.04. The company had revenue of $387.74 million during the quarter, compared to the consensus estimate of $388.72 million. Addus HomeCare had a net margin of 7.13% and a return on equity of 9.96%. The company’s revenue for the quarter was up 7.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.56 earnings per share. Equities analysts predict that Addus HomeCare will post 6.34 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. BlackRock Inc. bought a new stake in Addus HomeCare in the second quarter worth about $344,153,000. Dimensional Fund Advisors LP boosted its position in shares of Addus HomeCare by 11.8% during the 1st quarter. Dimensional Fund Advisors LP now owns 744,127 shares of the company’s stock valued at $69,689,000 after purchasing an additional 78,415 shares in the last quarter. Bank of America Corp DE bought a new position in shares of Addus HomeCare during the 2nd quarter valued at about $35,527,000. TimesSquare Capital Management LLC acquired a new position in shares of Addus HomeCare in the 2nd quarter worth approximately $31,502,000. Finally, Punch & Associates Investment Management Inc. acquired a new position in shares of Addus HomeCare in the 2nd quarter worth approximately $20,911,000. 95.35% of the stock is owned by institutional investors and hedge funds.

Key Addus HomeCare News

Here are the key news stories impacting Addus HomeCare this week:

• Positive Sentiment: UBS raised its price target to $160 from $145 and maintained a Buy rating; TD Cowen lifted its target to $145 from $131 and also maintained a Buy rating. UBS price-target report TD Cowen price-target report
• Positive Sentiment: ADUS recently reached a 52-week high. Its latest quarterly results included earnings per share of $1.83, ahead of the $1.79 consensus, while revenue increased 7% year over year. Addus hits a 12-month high
• Positive Sentiment: The company said it expects to close its AccentCare acquisition in the first quarter of 2027 and anticipates a full-year adjusted EBITDA margin around 13%; the deal may offer a growth opportunity, though execution remains ahead. AccentCare update
• Neutral Sentiment: Recent Zacks pieces discuss ADUS’s momentum and value-investing appeal, but the available summaries do not provide specific ratings or new estimates. Zacks momentum article Zacks value article
• Negative Sentiment: Quarterly revenue of $387.74 million was slightly below analysts’ $388.72 million estimate, tempering the otherwise positive earnings beat. Q3 earnings call highlights

Addus HomeCare Company Profile

Addus HomeCare Inc (NASDAQ: ADUS) provides in-home personal care, hospice and home health services to older adults, people with disabilities and other individuals who need assistance with daily living or medical care. Its services are designed to help clients remain safely and independently in their homes while supporting families and caregivers.

The company’s personal care services include assistance with bathing, dressing, grooming, meal preparation, housekeeping and other activities of daily living.